tbuckley/cabot-search huggingface dataset:
Behavior of borderline ovarian tumours (BOTs): Single institution experience
Authors: A. M. Oaknin, M. Romeo, F. Pons, X. Perez, P. Barretina, A. Vidal, L. Martí, M. Barahona, J. Germá, J. Ponce
Journal: Journal of Clinical Oncology (2009)

e16560 Background: To provide useful material for discussion, we report an analysis of a retrospective accrued, single-institution population with BOTs. Methods: 99 consecutive patients treated between April 1989 and July 2008, were reviewed for clinical characteristics, histology, surgical types, recurrence, and prognosis. Results: Median age was 46 years (19–77). 90% of patients were diagnosed by vaginal ultrasound as complex adnexal mass. CA-125 and CA19.9 was elevated in 60% and 30% of patients respectively. Primary treatment was surgery: laparotomy and laparoscopy (LT/LC) approach in 78% and 22% of patients, respectively. 33 patients (34%) underwent comprehensive staging operation; fertility-sparing surgery was performed in 18 patients (18%), and an incomplete staging in 47 patients (48%). The pathology results were: clear cell BOTs 1 case (1%); serous 42 cases (42.4%); mucinous in 56 women (56.6%) (46 intestinal/10 mullerian). 2 out of 56 mucinous BOTs were associated with pseudomixoma peritonei. Cyst-rupture was found in 22.5% and 38.9% of patients with LT/LC approach. 91women (93.8%) had stage I; 2 (2%) had stage II; and 6 (4.2%) had stage III disease. We identified 6 patients (7.8%) with noninvasive implants involving abdominal peritoneum (1), pelvic peritoneum (1), omentum (2) and both pelvic peritoneum and omentum (2). With a median follow-up of 3.6 years (0–18.4), we observed 5 recurrences (2 in contralateral ovary, 1 ipsilateral, 1 invasive peritoneal implant, and 1 para-aortic node). All were stage I disease at diagnosis. 2 out of 5 had incomplete staging, 3 had conservative surgery.3 cases were serous type. Histology recurrences were: 2 borderline, 2 invasive ovarian cancer, and 1 unknown. All patients underwent secondary cytoreduction achieving an optimal debulking in 4. Only one patient received chemotherapy. Two women died of intercurrent disease and 1 woman died of disease. The 5-year overall survival rate for entire cohort was 98.5% (95.6%-100%; CI95%). Conclusions: Our results confirm published data. Overall BOTs have an excellent prognosis. Proper staging is the cornerstone of treatment. Laparoscopy approach is associated with higher cyst rupture. Recurrences are more frequent after incomplete or conservative surgery. No significant financial relationships to disclose.
Abstract 19123: Extracellullar Matrix Derived from Cardiac Fibroblasts Is the Optimal Substrate for Expansion of Cardiac Stem Cells Ex Vivo
Authors: Clotilde Castaldo, Daria Nurzynska, Franca Di Meglio, Rita Miraglia, Veronica Romano, Ciro Bancone, Maurizio Cotrufo, Stefania Montagnani
Journal: Circulation (2010)

Cardiac Stem Cells (CSCc) contributing to cell turnover have been recently described in adult heart. The expression of extracellular matrix (ECM) proteins changes in qualitative and quantitative manner during heart remodeling. However, the influence of these changes on CSCs biology awaits investigation. The scope of the study was to evaluate the influence of fibronectin, laminin-1 and -2, collagen IV and of the natural ECM (cardiogel), obtained by culturing cardiac fibroblasts (CFs) isolated from normal (n=7) and pathological (n=8) hearts, on the biology of normal CSCs. Proliferation of CSCs, evaluated by BrdU incorporation, was 6,3-fold higher in the presence of laminin-1 and only 2-fold higher on laminin-2 with respect to control albumin. Apoptosis, detected in TUNEL assay, was as low as 1,8±0,4% on laminin-1 and was 2,8-fold, 5,4-fold and 8,5-fold higher on laminin-2, fibronectin and collagen IV, respectively. As revealed by immunofluorescence and immunoblotting, normal CFs synthesized mainly laminin-2...
Abstract 958: Cardiac MyBP-C Modulates Actomyosin Interactions: Evidence From Cardiac MyBP-c−/ − Mice
Authors: Yves Lecarpentier, Nicolas Vignier, Patricia Oliviero, Miguel Cortes-Morichetti, Lucie Carrier, Catherine Coirault
Journal: Circulation (2007)

The precise role of cardiac myosin binding protein C (cMyBP-C) on actomyosin interaction (AMI) remains unknown. We hypothesized that the lack of cMyBP-C impaired cardiac AMI. Experiments were performed on 16 weeks old cMyBP-C −/− (KO) and age-matched wild-type (WT) mice (n=20/group). In vitro mechanical and energetics properties were performed on left ventricular (LV) papillary muscles and Huxley’s equations were used to characterize AMI. In vitro motility assays were performed using myosin purified from LV. Myosin-based sliding velocities of actin filaments were analyzed at baseline, after pretreatment of the myosin solution with 10 umol of the catalytic subunit of PKA and/or in the presence of increasing amount of α-actinin, an actin-binding protein that acts as an internal load thereby providing an index of relative isometric force. Western-blot analysis was used to quantify cMyBP-C and phosphorylated cMyBP-C in myosin solutions. Compared to WT, both total tension and maximum shortening velocity were lower in KO (p&lt;0.001). The probability for myosin to be weakly bound to actin was higher in KO than in WT (8.6±0.3 vs. 5.4±0.2%, p&lt;0.05), whereas the number of strongly bound, high-force generated state cross-bridges was lower in KO (6.4±0.9 vs. 11.6±1.0 10 9 /mm 2 , p&lt;0.001). The unitary force per AMI was lower in KO than in WT (p&lt;0.01). At baseline, myosin-based velocities of actin were slower in KO than in WT (1.65±0.01 vs. 1.98±0.01 um/s, p&lt;0.01). The minimum amount of α-actinin needed to completely arrest the thin filament motility was significantly higher in WT than in KO (73.3±1.1 vs 29.1±0.1 ug/l, p&lt;0.001). As expected, cMyBP-C was present in WT myosin solution whereas cMyBP-C was not detected in KO. In WT, PKA induced a 1.6-fold increased in cMyBP-C phosphorylation (p&lt;0.01) associated with a 53±1% increase in the amount of α-actinin required to arrest thin filament motility (p&lt;0.001). PKA did not modify sliding velocity in WT. In KO, PKA had no effect on myosin sliding. We conclude that cMyBP-C regulates AMI by limiting inefficient cross-bridge formation and by enhancing the power stroke step. Phosphorylation status of cMyBP-C appears to play a critical role on cardiac contractility through a direct effect on the myosin molecular motor.
Abstract 14769: Bypassing Troubles: Relation of Exhaustion, Viral Burden, and Inflammation to Depressive Symptoms After Cardiac Surgery
Authors: Pamela S Miller, Lorraine S Evangelista, Joyce Newman Giger, Otoniel Martinez-Maza, Teresita Corvera-Tindel, Lynn V Doering
Journal: Circulation (2011)

Background: Inflammation is a mechanism by which depressive symptoms and vital exhaustion (VE) may confer increased risk of adverse cardiac outcomes. Objective: To elucidate the relationship of pos...
Abstract 10747: Age is Related to Interstitial Myocardial Fibrosis in Asymptomatic Adults: Magnetic Resonance T1 Mapping in the Multi-ethnic Study of Atherosclerosis (MESA)
Authors: Chia-Ying Liu, Yuan Chang Liu, Colin Wu, Anderson Armstrong, Gustavo J. Volpe, Rob J. van der Geest, Mei Liu, William G. Hundley, Antoinette Gomes, Songtao Liu, Marcelo Nacif, David A. Bluemke, Joao A.C. Lima
Journal: Circulation (2012)

Introduction:  Animal and human studies have demonstrated increased collagen deposition in senescent hearts. Cardiac magnetic resonance (CMR) indices of tissue composition using T 1  mapping are sensitive to the presence of myocardial fibrosis. The purpose of this study was to determine the relationship of CMR measures of tissue composition to age in MESA.   Methods:  585 women and 534 men (age 52-93) of the MESA cohort were evaluated using 1.5T CMR scanners. All participants did not have findings of delayed enhancement. Single slice T 1 mapping was performed at the mid-ventricular level before and at 12 and 25 minutes delay after administration of gadolinium (Magnevist; 0.15mmol/kg) using a Modified Look Locker Inversion Recovery sequence. Partition coefficient was determined by the slope of linear relationship of (1/T 1myo  vs. 1/T 1blood ) at various time points. Extracellular volume fraction (ECV) was derived accounting for the hematocrit. Multivariable regression analysis was performed, adjusting for traditional risk factors and left-ventricular structure.   Results:  Women had significantly higher partition coefficient, pre-contrast T 1 , and ECV, but lower post-contrast T 1  than men (Table 1). Linear regression analyses (Table 2) demonstrate that greater partition coefficient, pre-contrast T 1 , and ECV were associated with older age. Greater post-contrast T 1  and T 1  change (ΔT 1 /Δt) were also associated with older age. These relationships were stronger in men than in women.   Conclusion:  CMR parameters that are associated with fibrosis were related to older age in the MESA study. These fibrosis indices suggest greater age-related change in men than women.
DNA repair and UV exposure influence important characteristics of non-melanoma skin cancer
Authors: Jaime L. Matta, Jaime L. Villa, Abigail Ruiz, Roy A. Armstrong, Juan M. Ramos
Journal: Cancer Research (2004)

Proc Amer Assoc Cancer Res, Volume 45, 2004

1492 

Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), collectively known as non-melanoma skin cancer (NMSC) are the most common cancer worldwide. UV radiation is an important risk factor for NMSC because of DNA damage and carcinogenesis promotion. DNA repair capacity (DRC) is an important and independent risk factor for NMSC. We investigated the relationship between UV exposure (dose) and DRC to determine how these factors influence key NMSC characteristics; BCC:SCC ratio, number of tumors and tumor site. The following hypotheses were tested: 1) The ratio of BCC:SCC decreases with increasing UV dose, 2) Number of NMSC tumors is higher with increasing UV dose, 3) UV dose determines the site of NMSC tumors, 4) Participants exposed to low UV dose with tumors in sun protected areas have a lower DRC compared with the same group that have tumors in sun exposed areas. Participants (n=281) having 303 tumors were recruited over a forty-four month period. A questionnaire was administered to solicit hours per month each participant was exposed to UV and the duration of UV exposure in years. Environmental UVA and UVB doses were collected for five continuous years in La Parguera, PR using a GUV spectroradiometer. A minimum of three hours of continuous UV exposure per week (400 kJ•m2•wk^-1) was the threshold between low and high UV exposure. Very high UV exposure was defined by an exposure exceeding 15 years for a minimal accumulation of 323,000 kJ.m2. Sun exposed areas were defined as the head, neck, and outer surface of the arms. The inner surface of the arms, back, legs, and rest of the body was defined as sun protected areas. The ratio of BCC:SCC was 3.5 in the 303 tumors studied. This ratio decreased as the UV exposure of the participants increased. Participants with low, high and very high UV exposure had a ratio of 4.4, 4.0, and 2.3 respectively. The number of tumors was the same in participants with low and high UV exposure (1.9 tumors per person), but it increased sharply in the very high UV group (3.6 tumors per person). NMSC tumors are more frequent in sun exposed areas in participants that received higher UV doses and conversely tumors were more frequent in sun protected areas exposed to lower UV doses. Participants exposed to low UV doses having tumors in sun protected areas had a 57% significantly lower (p<0.001) DRC in relation to the same group that had tumors in sun exposed areas. UV dose had a strong influence in terms of the location, number and BCC:SCC ratio of NMSC in the population studied. DRC was the most important risk factor studied in influencing the presence of tumors in sun protected areas. Supported by grants 2G12RR0350-19 from NIH-RCMI and NAG-2-1385 NASA to J.M.
Abstract 15688: Electrocardiographic Patterns Differentiating "Apical Ballooning" From Anterior Myocardial Infarction
Authors: Birke Schneider, Kay Peters, Udo Desch, Jürgen Stein
Journal: Circulation (2014)

Introduction: Left ventricular apical ballooning (AB) mimics anterior myocardial infarction (AMI). This study assessed if the ECG can differentiate between these two syndromes with a similar clinical presentation. Methods: Among 2086 patients (pts) with an ACS, 33 (1.6%) with AB were identified (29 f, 4 m, median age 77 years) and compared to 28 consecutive age and sex matched AMI pts undergoing PCI of the LAD with similar findings on LV angiography. Results: AB pts arrived at the hospital later after symptom onset (median 21 vs 5 hours; p&lt;0.001). On the admission ECG, the number of leads with ST-segment elevation (4 [3-6] vs 5 [5-7], p=0.005) and the magnitude of ST-segment elevation (0.7 [0.5-0.9] vs 0.9 [0.7-1.5] mV, p=0.002) were greater in AMI. Reciprocal ST-segment depression was similar (27% vs 54%, p=ns). A positive T wave in aVR was more frequent in AB (49% vs 7%, p&lt;0.001). During follow-up, AB pts had more leads with T-wave inversion (8 [8-9] vs 6 [5-8], p&lt;0.001) and a larger magnitude of T-wave inversion (2.9 [2.2-4.6] vs 1.4 [0.9-2.3] mV, p&lt;0.001). T-wave inversion was similar in I, aVL and V2-V5. AB pts, however, showed negative T-waves also in lead II (74% vs 22%, p&lt;0.001), III (34% vs 4%, p=0.004), aVF (51% vs 11%, p=0.001) and a positive T wave in aVR (100% vs 70%, p=0.005). The QTc interval was longer in AB (515 [482-543] vs 458 [435-484] ms, p&lt;0.001). An abnormal Q wave on admission was more frequent in AMI (21% vs 79%, p&lt;0.001) and persisted but was absent in AB at discharge (0% vs 61%, p&lt;0.001). Ventricular tachycardia was similar (2% vs 14%, p=ns) but atrial fibrillation occurred only in AB (21% vs 0%, p=0.013). The ECG normalized in all AB but in only 1 AMI pt (p&lt;0.001). Overall, despite a similar ejection fraction (54±15 vs 55±13 %) and lower troponin I values (7.5±6.9 vs 238±221 ng/ml, p&lt;0.001), AB pts developed significantly more adverse events compared to AMI pts (52% vs 18%, p&lt;0.008). Conclusion: ECG patterns in AB are significantly different from those in AMI. On admission, the extent of ST-segment elevation and the number of Q waves are greater in AMI. During follow-up, no Q wave, a longer QTc interval, a greater extent of T-wave inversion and a positive T wave in aVR are typical findings in AB. Adverse events are more frequent in AB than in AMI.
Synergy between IL-6 and soluble IL-6 receptor enhances bone morphogenetic protein-2/absorbable collagen sponge-induced bone regeneration via regulation of BMPRIA distribution and degradation
Authors: Ru-Lin Huang, Gang Chen, Wenjin Wang, Tanja Herller, Yun Xie, Bin Gu, Qingfeng Li
Journal: Biomaterials (2015)
Abstract 8761: An International Collaborative Meta-Analysis on Pharmacologic Therapy of Acute Pericarditis
Authors: Giuseppe Biondi-Zoccai, Marzia Lotrionte, Massimo Imazio, Antonio Brucato, Pietro Di Pasquale, Antonio Abbate, Marja Raatikka, Imad Sheiban, Fiorenzo Gaita
Journal: Circulation (2010)
Abstract 15368: Prognostic Value Of Inflammatory, Extracellular Matrix And Necrosis Biomarkers, And Their Relationship With Neurohormonal Biomarkers And Outcome In Patients With Acute Heart Failure. Data From The Everest Trial
Authors: Daniela Dobre, Anne Pizard, Patrick Rossignol, Mary Kwasny, Angela Fought, Liliana Grinfeld, Mihai Gheorghiade, Faiez Zannad
Journal: Circulation (2011)

Objectives: Inflammation, extracellular matrix (ECM) turnover and cell injury are involved in the pathophysiology of acute heart failure (AHF), at least partly as a result of neurohormonal activati...
长期服用阿司匹林能预防癌症吗？——可能有效，但回答此问题需特别设计的临床试验
Authors: 孙薇
Journal: BMJ (2011)

阿司匹林的心脏保护作用得到公认。一项对初级预防随机对照试验（RCTs）的个体受试者数据进行的荟萃（meta）分析表明，阿司匹林能减少非致死性心肌梗死发生的相对风险约20％。总的来说，其治疗的风险（即严重胃肠道出血和颅外出血）与收益大致相同，因此并不推荐常规使用阿司匹林作为一级预防方案。meta分析并没有得出任何阿司匹林可能降低癌症病死率的结果，
Abstract 1707: Admission Glucose and Cardiovascular Outcomes in Patients With Non-ST Elevation ACS: Observations From the MERLIN-TIMI 36 Trial
Authors: Marc Bonaca, Prakash Deedwania, Darren K McGuire, Benjamin M Scirica, Sabina A Murphy, David A Morrow
Journal: Circulation (2009)

The association of hyperglycemia and adverse cardiac events in patients presenting with acute coronary syndrome has been described. However, more recently a possible relationship of hypoglycemia an...
Abstract 108: Use of an Impedance Threshold Device Improves Survival in a Suburban EMS System
Authors: Levon Vartanian, Gregory Wolf, Allen Sims, Kevin Traynor
Journal: Circulation (2006)

Introduction: The 2005 AHA guidelines recently recommended (Class IIa) the use of an impedance threshold device (ITD) to increase circulation and return of spontaneous circulation (ROSC) rates in patients in cardiac arrest. Hypothesis: We assessed the hypothesis that adding an ITD to standard BLS and ALS resuscitation efforts would improve short-term survival in patients with out-of-hospital cardiac arrest from all causes when compared to historical controls. Methods: Cypress Creek EMS (population 400K) covers a suburban area North of Houston (TX) in Harris County. From 8/05– 4/06, 104 patients in cardiac arrest were prospectively treated with an ITD (ResQPOD®) and survival results were compared to historical controls (n=143) from 8/04–7/05 when an ITD was not in use. The primary endpoint was ROSC. A Chi square test was used for statistical analysis. Age, gender and EMS response time (~8 min) were evenly matched between groups. The ITD was used on all patients in cardiac arrest (all etiologies) who were >...
Induction erlotinib therapy in stage IIIA-N2 non-small cell lung cancer.
Authors: W. Zhong, X. Yang, R. Liao, Q. Nie, X. Zhang, J. Su, Q. Zhou, C. Xu, J. Yang, Y. Wu
Journal: Journal of Clinical Oncology (2010)

TPS284 Background: Stage IIIA non-small cell lung cancer (NSCLC) is seen in a relatively heterogeneous group of patients with ipsilateral mediastinal (N2) lymph node involvement. The relative roles of different treatment modalities are not clear. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) may result in dramatic responses in patients with pulmonary adenocarcinoma carrying EGFR activating mutations. In case reports, the efficacy of perioperative EGFR-TKI therapy in patients with locally advanced NSCLC harboring EGFR gene mutations was satisfactory. Although no prospective data support the use of EGFR-TKIs as induction therapy in stage IIIA-N2 NSCLC, their low toxicity profile and the possibility of a rapid tumor response suggests that prospective trials are required. Therefore, this study evaluated the value of induction erlotinib therapy in IIIA-N2 NSCLC selected by EGFR gene analysis and explored a new treatment strategy for this subset. Erlotinib specifically targets the EGFR TK domain, which is highly expressed and occasionally mutated in various forms of cancer. It binds in a reversible fashion to the adenosine triphosphate (ATP) binding site of the receptor. Methods: A two-stage phase II trial of induction EGFR-TKI therapy is currently recruiting participants (ClinicalTrials.gov identifier: NCT00600587). Patients with resectable stage IIIA-N2 NSCLC confirmed by mediastinoscopy or PET/CT were assigned to the induction erlotinib therapy arm (150 mg erlotinib taken once daily and continued uninterrupted for 42 d before evaluation and thoracotomy/radiotherapy) or the induction gemcitabine/carboplatin (GC) arm based on the EGFR mutation analysis. Study type: Interventional. Study Design: Active control, factorial assignment, nonrandomized, open label, safety/efficacy study, treatment. Primary outcome measures: Response to induction therapy, disease-free survival. Estimated enrollment: Fifteen cases in the erlotinib arm are needed in the first stage, and 46 cases in the second stage. At present, six patients have been assigned to the induction erlotinib therapy arm and seven to the induction GC arm. No significant financial relationships to disclose.
Deputising general practitioners' role in emergencies
Authors: J. Fleming
Journal: BMJ (1995)

Lessons for both doctors involved

EDITOR,--I read J N Rawlinson's letter about the care given to a neighbour by a deputising doctor with some concern.1 We all have anecdotes that show doctors or departments to be less than perfect, but we are all trying to provide the best service we can despite the pressures we face.

I am not the doctor this tale was about, but, as a …
Abstract 2257: <i>KCNJ2</i> Mutations in Patients Referred for Catecholaminergic Polymorphic Ventricular Tachycardia Gene Screening
Authors: Yanfei Ruan, Juliane Theilade, Mirella Memmi, Luciana D Giuli, Nicoletta Rizzi, Fernando E Cruz Filho, Carlo Napolitano, Silvia G Priori
Journal: Circulation (2007)

Background : Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited arrhythmogenic disease characterized by adrenergically mediated polymorphic or bidirectional ventricular tachycardia (BVT). Andersen-Tawil syndrome (ATS1), which are mainly caused by KCNJ2 mutations, phenocopies CPVT and may manifest the typical adrenergically mediated BVT. The purpose of this study was assess whether patients (pts) lacking periodic paralysis typical of ATS1 and diagnosed as CPVT because of BVT carry KCNJ2 mutations. Methods and Results : Mutational analysis of KCNJ2 was performed in 23 RyR2 and CASQ2 genotype-negative CPVT pts with normal QT interval. Two novel missense mutations (S220I and T305I) were identified. Mutations were absent in &gt;400 reference alleles. Both of the pts present exercise or isoproterenol induced BVT, baseline ECG with prominent U wave and mild facial abnormalities. In vitro characterization showed that no current is detectable when S220I and T305I mutants clones are expressed; on the contrary co-expression of WT and mutant KCNJ2 to mimic heterozygosis present in patients, caused significant dominant negative effect (see figure ). Confocal laser microscopy revealed normal sarcolemmal localization of the mutant channels and of the heterozygous channels. Conclusions : KCNJ2 mutation with loss of function are present in a minority of pts with clinical diagnosis of CPVT. Given the limited number of CPVT pts with KCNJ2 mutations it is impossible to determine whether their prognosis is identical to that of RyR2 and CASQ2 related CPVT. Screening of KCNJ2 should be considered in CPVT pts without mutations in RyR2 and CASQ2 genes.